Handbook of Immunological Properties of Engineered Nanomaterials

Dr Dobrovolskaia is a Principal Scientist and a Head of Immunology section at the NCL. Dr Dobrovolskaia directs characterization related to a nanomaterials' interaction with components of the immune system. She monitors acute/adverse effects of nanoparticles as they relate to the immune system, both in vitro and in animal models. Dr Dobrovolskaia is also responsible for the development, validation and performance qualification of in vitro and ex vivo assays to support preclinical characterization of nanoparticles, and for monitoring nanoparticle purity from biological contaminants such as bacteria, yeast, mold and endotoxin. Additionally, she leads structure activity relationship studies aimed at identifying the relationship between nanoparticle physicochemical properties and their interaction with macrophages, components of the blood coagulation cascade, and complement systems. Prior to joining the NCL, Dr Dobrovolskaia worked as a Research Scientist in a GLP laboratory at PPD Development, Inc. in Richmond, VA. She was responsible for the design, development and validation of bioanalytical ligand-binding assays to support pharmacokinetic and toxicity studies in a variety of drug development projects. She received her M S degree from the Kazan State University in Russia, her PhD from the N N Blokhin Cancer Research Center of the Russian Academy of Medical Sciences in Moscow, Russia, and completed two postdoctoral trainings in immunology at the National Cancer Institute in Frederick, MD and the University of Maryland in Baltimore, MD. Her areas of expertise include cell signaling, innate immunity, immunogenicity and analytical methodology.

Dr McNeil serves as the Director of the Nanotechnology Characterization Laboratory (NCL) for Leidos Biomedical Research and Frederick National Laboratory for Cancer Research, where he coordinates preclinical characterization of nanotech cancer therapeutics and diagnostics. At the NCL, Dr McNeil leads a team of scientists responsible for testing candidate nanotech drugs and diagnostics, evaluating safety and efficacy, and assisting with product development — from discovery-level, through scale-up and into clinical trials. NCL has assisted in characterization and evaluation of more than 300 nanotechnology products, several of which are now in human clinical trials. Dr McNeil is a member of several working groups on nanomedicine, environmental health and safety, and other nanotechnology issues. He is an invited speaker to numerous nanotechnology-related conferences and has several patents pending related to nanotechnology and biotechnology. He is also a Vice President of Leidos Biomedical Research. Prior to establishing the NCL, he served as a Senior Scientist in the Nanotech Initiatives Division at Leidos where he transitioned basic nanotechnology research to government and commercial markets. He advises industry and State and US Governments on the development of nanotechnology and is a member of several governmental and industrial working groups related to nanotechnology policy, standardization and commercialization. Dr McNeil's professional career includes tenure as an Army Officer, with tours as Chief of Biochemistry at Tripler Army Medical Center, and as a Combat Arms officer during the Gulf War. He received his bachelor's degree in chemistry from Portland State University and his doctorate in cell biology from Oregon Health Sciences University.

Volume 1: Key Considerations for Nanoparticle Characterization Prior to Immunotoxicity Studies:Immunological Properties of Engineered Nanomaterials: An Introduction (Dobrovolskaia MA & Mcneil SE); Importance of Physicochemical Characterization Prior to Immunological Studies (Clogston JD & Patri AK); Nanoparticle Sterility and Sterilization of Nanomaterials (Subbarao N); Sterilization Case Study 1: Consequences of Different Sterilization Techniques on Gold Nanoparticles (Gonzalez-Fernandez A et al.); Sterilization Case Study 2: Effects of Sterilization Techniques on Silver Nanoparticles (Dobrovolskaia MA et al.); Surface Contaminants and Their Role in Nanoparticle Immunotoxicity (Grainger D et al.); Endotoxin and Engineered Nanomaterials (Dobrovolskaia MA & Mcneil SE); Endotoxin Case Study: Nanoparticle Interference with Gel-Clot LAL (Kraegeloh A et al.); Regulatory Considerations (Weaver J. et al.); In Vitro Assays to Monitor Nanoparticle Interaction with Components of the Immune System (Dobrovolskaia MA & Mcneil SE); Animal Models to Monitor Adverse Effects of Nanomaterials on the Immune System (Smith M et al.); Understanding Correlation Between In Vitro and In Vivo Immunological Assays for Engineered Nanomaterials (Dobrovolskaia MA & Mcneil SE); Volume 2: Haematocompatibility of Engineered Nanomaterials:Interaction with Plasma Proteins as It Relates to Particle Biodistribution (Nienhaus U and Treuel L); Protein Binding Case Study 1: Understanding Relationship Between Protein Corona and Nanoparticle Toxicity (Dobrovolskaia M et al.); Mathematical Modeling of Protein Corona and Its Implication in the Design of Nanotechnology-Based Drug Delivery Systems (Cedervall T); Effects on Erythrocytes (Brown R et al.); Effects on Endothelial Cells (Simak J); Effects on Plasma Coagulation (Simak J); Effects on Platelets (Simak J); Nanoparticles and Coagulation System: Benefits of Nanotechnology and Safety Considerations (Ilinskaya A & Dobrovolskaia M A); Complement Activation by Nanomaterials (Salvador-Morales C & Sim R); Complement Activation Case Study: Induction of CARPA by PEGylated Liposomes (Szebeni J et al.); Nanoparticles and the Lymphatic System (Khan W and Sistla); Volume 3: Engineered Nanomaterials and the Immune Cell Function:Bidirectional Interaction Between Nanoparticles and Cells of the Mononuclear Phagocytic System (Zamboni W et al.); Case Study: Application of Leukolike Technology to Camouflage Nanoparticles from the Immune Recognitiont (Tasciotti E et al.); The Effects of Nanoparticles on Dendritic Cells (Fesenkova V); The Effects of Nanoparticles on Bone Marrow Cells (Dadacheva E); Nanoparticles and Vaccine Delivery and Efficacy (Xiang S et al.); Undesirable Adjuvanticity of Nanoparticles and Its Implication in Modulation of T Helper Responses (Inoue K); Immunosuppressive and Anti-Inflammatory Properties of Engineered Nanomaterials (Ilinskaya A & Dobrovolskaia MA); Nanoparticles as Drug Deliveyr Vehicels for the Therapy of Inflammatory Disorders (Menon D et al.); Application of Nanoparticles for the Delivery of Anti-Viral Drugs (Liptrott N et al.); Nanostructures and Allergy (Lorenzo-Abalde S & Gonzalez-Fernandez A); Nanoparticles and Antigenicity (Dobrovolskaia MA); Nanoparticles and Tumor Immunity Case Study: Application of Iron Oxide Nanoparticle to CD8+ T Cell Response Against Primary Response Against Primary and Secondary Tumors Through Induction of Local Hyperthermia (Fiering S et al.);